RaySearch Q1 2022 Order Intake Jumps 88%

Reuters02-20

RaySearch Q1 2022 Order Intake Jumps 88%

RaySearch Laboratories’ management said demand for its radiotherapy software is recovering as pandemic effects fade, with Q1 2022 order intake up 88% year-on-year and net sales reaching a record SEK 208 million for a first quarter. The company reported operating profit of SEK 30 million (14% margin) and an all-time-high order backlog of SEK 1,489 million, while highlighting new particle therapy orders and a collaboration agreement with GE Healthcare to develop a radiotherapy simulation and treatment planning workflow combining RayStation with GE’s simulator systems. Management also noted growing interest in RayCare, confirmed RayCommand’s first clinical use at MedAustron, and said it is “100% sure” RayCare interoperability with Varian’s TrueBeam will be in place before year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RaySearch Laboratories AB published the original content used to generate this news brief on February 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612932892?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612932892","market":"nz","top_or_hot":-1,"title":"RaySearch Q1 2022 Order Intake Jumps 88%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RaySearch Q1 2022 Order Intake Jumps 88%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RaySearch Laboratories’ management said demand for its radiotherapy software is recovering as pandemic effects fade, with Q1 2022 order intake up 88% year-on-year and net sales reaching a record SEK 208 million for a first quarter. The company reported operating profit of SEK 30 million (14% margin) and an all-time-high order backlog of SEK 1,489 million, while highlighting new particle therapy orders and a collaboration agreement with GE Healthcare to develop a radiotherapy simulation and treatment planning workflow combining RayStation with GE’s simulator systems. Management also noted growing interest in RayCare, confirmed RayCommand’s first clinical use at MedAustron, and said it is “100% sure” RayCare interoperability with Varian’s TrueBeam will be in place before year-end.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RaySearch Laboratories AB published the original content used to generate this news brief on February 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RaySearch Q1 2022 Order Intake Jumps 88%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRaySearch Q1 2022 Order Intake Jumps 88%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-20 23:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RaySearch Q1 2022 Order Intake Jumps 88%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RaySearch Laboratories’ management said demand for its radiotherapy software is recovering as pandemic effects fade, with Q1 2022 order intake up 88% year-on-year and net sales reaching a record SEK 208 million for a first quarter. The company reported operating profit of SEK 30 million (14% margin) and an all-time-high order backlog of SEK 1,489 million, while highlighting new particle therapy orders and a collaboration agreement with GE Healthcare to develop a radiotherapy simulation and treatment planning workflow combining RayStation with GE’s simulator systems. Management also noted growing interest in RayCare, confirmed RayCommand’s first clinical use at MedAustron, and said it is “100% sure” RayCare interoperability with Varian’s TrueBeam will be in place before year-end.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RaySearch Laboratories AB published the original content used to generate this news brief on February 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL8cTnpn:1","article_id":"2612932892","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612932892","pubTimestamp":1771602395,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"RaySearch Laboratories’ management said demand for its radiotherapy software is recovering as pandemic effects fade, with Q1 2022 order intake up 88% year-on-year and net sales reaching a record SEK 208 million for a first quarter. The company reported operating profit of SEK 30 million  and an all-time-high order backlog of SEK 1,489 million, while highlighting new particle therapy orders and a collaboration agreement with GE Healthcare to develop a radiotherapy simulation and treatment planning workflow combining RayStation with GE’s simulator systems. Management also noted growing interest in RayCare, confirmed RayCommand’s first clinical use at MedAustron, and said it is “100% sure” RayCare interoperability with Varian’s TrueBeam will be in place before year-end.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpose","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","GEHC":"GE HEALTHCARE TECHNOLOGIES INC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Raysearch 2022年第一季度订单量猛增88%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GEHC":0.9},"content_text":"RaySearch Q1 2022 Order Intake Jumps 88%\n    \n\n        RaySearch Laboratories’ management said demand for its radiotherapy software is recovering as pandemic effects fade, with Q1 2022 order intake up 88% year-on-year and net sales reaching a record SEK 208 million for a first quarter. The company reported operating profit of SEK 30 million (14% margin) and an all-time-high order backlog of SEK 1,489 million, while highlighting new particle therapy orders and a collaboration agreement with GE Healthcare to develop a radiotherapy simulation and treatment planning workflow combining RayStation with GE’s simulator systems. Management also noted growing interest in RayCare, confirmed RayCommand’s first clinical use at MedAustron, and said it is “100% sure” RayCare interoperability with Varian’s TrueBeam will be in place before year-end.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RaySearch Laboratories AB published the original content used to generate this news brief on February 20, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612932892","isCrawlerRequest":true}